TrialJournal of neuro-oncology2015

An open-label, two-stage, phase II study of bevacizumab and lapatinib in children with recurrent or refractory ependymoma: a collaborative ependymoma research network study (CERN).

Mariko DeWire et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.